The FDA delivered a second blow to the makers of rivaroxaban (Xarelto) in their bid to treat patients with acute coronary syndromes (ACS).

New data shed some light on the adverse events associated with extended-release niacin and the antiflushing agent laropiprant in the Heart Protection Study 2-Treatment of HDL ...

A Mediterranean diet supplemented with either extra virgin olive oil or mixed nuts may cut the risk of cardiovascular events by as much as 30% in subjects at high risk of developing heart disease...